In the old model for drug discovery, R&D is needed to provide a regular crop of new drug prospects to replace the therapies coming off patent. But that's not so in the generics world. Some of India's top generics companies are spinning off their R&D operations into separate companies. Ranbaxy Laboratories and Dr. Reddy's say that these spinoffs make more sense.
- read the report [1] from the Financial Times
Related Articles:
Ranbaxy spins off R&D unit. Report [2]
Ranbaxy touts R&D abilities in new discovery pact. Report [3]
Dr. Reddy's make risky biogenerics move. Report [4]
Links:
[1] http://www.ft.com/cms/s/dd95ccde-8082-11dc-9f14-0000779fd2ac,Authorised=false.html?_i_location=http%3A%2F%2Fwww.ft.com%2Fcms%2Fs%2F1%2Fdd95ccde-8082-11dc-9f14-0000779fd2ac.html
[2] http://www.fiercebiotech.com/story/ranbaxy-spins-r-d-unit/2007-10-19?utm_medium=rss&utm_source=rss
[3] http://www.fiercebiotech.com/story/ranbaxy-touts-rd-abilities-in-new-discovery-pact/2007-02-07
[4] http://www.fiercebiotech.com/node/7447